Diabetes and cancer

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 1, 2014, Pages 167-185

  Zelenko, Zara ^a   Gallagher, Emily Jane ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Diabetes mellitus; Hyperglycemia; Hyperinsulinemia; Inflammation; Metabolic syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; GLUCOSE; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

CANCER INCIDENCE; CANCER MORTALITY; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; METASTASIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; COMPLICATION; IMMUNOLOGY; METABOLISM; NEOPLASMS;

DIABETES MELLITUS, TYPE 2; HUMANS; NEOPLASMS;

EID: 84896716165     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.09.008     Document Type: Review

References (111)

1. Kaplan M.A., Pekkolay Z., Kucukoner M., et al. Type 2 diabetes mellitus and prognosis in early stage breast cancer women. Med Oncol 2012, 29(3):1576-1580.
2. Liu X., Ji J., Sundquist K., et al. The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer 2012, 118(5):1353-1361.
3. Campbell P.T., Newton C.C., Patel A.V., et al. Diabetes and cause-specific mortality in a prospective cohort of one million U.S adults. Diabetes Care 2012, 35(9):1835-1844.
4. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S adults. NEngl J Med 2003, 348(17):1625-1638.
5. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004, 88(4):787-835. ix.
6. LeRoith D., Gavrilova O. Mouse models created to study the pathophysiology of type 2 diabetes. Int J Biochem Cell Biol 2006, 38(5-6):904-912.
7. Onitilo A.A., Engel J.M., Glurich I., et al. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control 2012, 23(6):967-981.
8. Gordon-Dseagu V.L., Shelton N., Mindell J.S. Epidemiological evidence of a relationship between type-1 diabetes mellitus and cancer: a review of the existing literature. Int J Cancer 2013, 132(3):501-508.
9. Shu X., Ji J., Li X., et al. Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med 2010, 27(7):791-797.
10. Hemminki K., Houlston R., Sundquist J., et al. Co-morbidity between early-onset leukemia and type 1 diabetes-suggestive of a shared viral etiology?. PLoS One 2012, 7(6):e39523.
11. Gallagher E.J., Leroith D., Karnieli E. The metabolic syndrome-from insulin resistance to obesity and diabetes. Med Clin North Am 2011, 95(5):855-873.
12. Haggstrom C., Stocks T., Rapp K., et al. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer 2011, 128(8):1890-1898.
13. Bjorge T., Lukanova A., Jonsson H., et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010, 19(7):1737-1745.
14. Borena W., Strohmaier S., Lukanova A., et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012, 131(1):193-200.
15. Stocks T., Rapp K., Bjorge T., et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 2009, 6(12):e1000201.
16. Borena W., Stocks T., Jonsson H., et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 2011, 22(2):291-299.
17. Stocks T., Van Hemelrijck M., Manjer J., et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension 2012, 59(4):802-810.
18. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
19. Renehan A.G., Tyson M., Egger M., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371(9612):569-578.
20. Adami H.O., McLaughlin J., Ekbom A., et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991, 2(5):307-314.
21. Chari S.T., Leibson C.L., Rabe K.G., et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005, 129(2):504-511.
22. Zhang P.H., Chen Z.W., Lv D., et al. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health 2012, 12(1):567.
23. Haslam D.W., James W.P. Obesity. Lancet 2005, 366(9492):1197-1209.
24. Vigneri P., Frasca F., Sciacca L., et al. Diabetes and cancer. Endocr Relat Cancer 2009, 16(4):1103-1123.
25. Boyle P., Boniol M., Koechlin A., et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012, 107(9):1608-1617.
26. El-Serag H.B. Hepatocellular carcinoma. NEngl J Med 2011, 365(12):1118-1127.
27. Arase Y., Kobayashi M., Suzuki F., et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013, 57(3):964-973.
28. Hsing A.W., Tsao L., Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000, 85(1):60-67.
29. Cheng K.C., Chen Y.L., Lai S.W., et al. Risk of esophagus cancer in diabetes mellitus: a population-based case-control study in Taiwan. BMC Gastroenterol 2012, 12:177.
30. Wang J.Y., Chao T.T., Lai C.C., et al. Risk of colorectal cancer in type 2 diabetic patients: a population-based cohort study. Jpn J Clin Oncol 2013, 43(3):258-263.
31. Pan A., Malik V.S., Hu F.B. Exporting diabetes mellitus to Asia: the impact of western-style fast food. Circulation 2012, 126(2):163-165.
32. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414(6865):782-787.
33. Seshasai S.R., Kaptoge S., Thompson A., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. NEngl J Med 2011, 364(9):829-841.
34. Zanders M.M., Boll D., van Steenbergen L.N., et al. Effect of diabetes on endometrial cancer recurrence and survival. Maturitas 2013, 74(1):37-43.
35. Hwang A., Narayan V., Yang Y.X. Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study. Cancer 2013, 119(2):404-410.
36. Redaniel M.T., Jeffreys M., May M.T., et al. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control 2012, 23(11):1785-1795.
37. Peairs K.S., Barone B.B., Snyder C.F., et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. JClin Oncol 2011, 29(1):40-46.
38. Mitin T., Chen M.H., Zhang Y., et al. Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. JUrol 2011, 186(6):2233-2237.
39. Yeh H.C., Platz E.A., Wang N.Y., et al. Aprospective study of the associations between treated diabetes and cancer outcomes. Diabetes Care 2012, 35(1):113-118.
40. D'Amico A.V., Braccioforte M.H., Moran B.J., et al. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77(5):1329-1337.
41. Snyder C.F., Stein K.B., Barone B.B., et al. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 2010, 13(1):58-64.
42. Lawlor D.A., Smith G.D., Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 2004, 15(3):267-275.
43. Ouchi N., Parker J.L., Lugus J.J., et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11(2):85-97.
44. Giovannucci E., Harlan D.M., Archer M.C., et al. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33(7):1674-1685.
45. Yang Y., Mauldin P.D., Ebeling M., et al. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer 2012, 119(8):1512-1520.
46. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351(9113):1393-1396.
47. Yee D., Paik S., Lebovic G.S., et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989, 3(3):509-517.
48. Ikushima H., Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010, 10(6):415-424.
49. Samani A.A., Yakar S., LeRoith D., et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28(1):20-47.
50. Creighton C.J., Casa A., Lazard Z., et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. JClin Oncol 2008, 26(25):4078-4085.
51. Walsh L.A., Damjanovski S. IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-beta1 resulting in epithelial to mesenchymal transition. Cell Commun Signal 2011, 9(1):10.
52. Kim H.J., Litzenburger B.C., Cui X., et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 2007, 27(8):3165-3175.
53. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17(5):548-558.
54. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. JClin Invest 2009, 119(6):1420-1428.
55. Tornell J., Carlsson B., Pohjanen P., et al. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. JSteroid Biochem Mol Biol 1992, 43(1-3):237-242.
56. de Ostrovich K.K., Lambertz I., Colby J.K., et al. Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis invivo. Am J Pathol 2008, 173(3):824-834.
57. Wu Y., Cui K., Miyoshi K., et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003, 63(15):4384-4388.
58. Konijeti R., Koyama S., Gray A., et al. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts. Mol Cancer Ther 2012, 11(7):1539-1546.
59. Reidy D.L., Vakiani E., Fakih M.G., et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. JClin Oncol 2010, 28(27):4240-4246.
60. Schmitz S., Kaminsky-Forrett M.C., Henry S., et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 2012, 23(8):2153-2161.
61. Weickhardt A., Doebele R., Oton A., et al. Aphase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. JThorac Oncol 2012, 7(2):419-426.
62. Becker S., Dossus L., Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009, 115(2):86-96.
63. Goodwin P.J., Ennis M., Pritchard K.I., et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. JClin Oncol 2002, 20(1):42-51.
64. Lipscombe L.L., Goodwin P.J., Zinman B., et al. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008, 109(2):389-395.
65. Mauro L., Bartucci M., Morelli C., et al. IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. JBiol Chem 2001, 276(43):39892-39897.
66. Rodriguez-Viciana P., Warne P.H., Vanhaesebroeck B., et al. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 1996, 15(10):2442-2451.
67. Larue L., Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24(50):7443-7454.
68. Grille S.J., Bellacosa A., Upson J., et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003, 63(9):2172-2178.
69. Frasca F., Pandini G., Scalia P., et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999, 19(5):3278-3288.
70. Harrington S.C., Weroha S.J., Reynolds C., et al. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res 2012, 22(3-4):108-115.
71. Thissen J.P., Ketelslegers J.M., Underwood L.E. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994, 15(1):80-101.
72. Novosyadlyy R., Lann D.E., Vijayakumar A., et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010, 70(2):741-751.
73. Fernandez A.M., Kim J.K., Yakar S., et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001, 15(15):1926-1934.
74. Ferguson R.D., Novosyadlyy R., Fierz Y., et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 2012, 14(1):R8.
75. Zhang H., Fagan D.H., Zeng X., et al. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010, 29(17):2517-2527.
76. Shikata K., Ninomiya T., Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 2013, 104(1):9-14.
77. Sieri S., Muti P., Claudia A., et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 2012, 130(4):921-929.
78. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. JNatl Cancer Inst 2004, 96(24):1805-1806.
79. Zeng L., Biernacka K.M., Holly J.M., et al. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer 2010, 17(2):539-551.
80. Zhou L., Xue H., Yuan P., et al. Angiotensin AT1 receptor activation mediates high glucose-induced epithelial-mesenchymal transition in renal proximal tubular cells. Clin Exp Pharmacol Physiol 2010, 37(9):e152-e157.
81. Pan B., Ren H., He Y., et al. HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. Clin Cancer Res 2012, 18(5):1246-1256.
82. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113(6):685-700.
83. Al Moustafa A.E., Achkhar A. Yasmeen A: EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. Front Biosci (Schol Ed) 2012, 4:671-684.
84. Bhattacharyya S., Sul K., Krukovets I., et al. Novel tissue-specific mechanism of regulation of angiogenesis and cancer growth in response to hyperglycemia. JAm Heart Assoc 2012, 1(6):e005967.
85. Haffner S.M. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003, 92(4A):18J-26J.
86. Vendramini-Costa D.B., Carvalho J.E. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012, 18(26):3831-3852.
87. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259(5091):87-91.
88. Uysal K.T., Wiesbrock S.M., Marino M.W., et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389(6651):610-614.
89. Aggarwal B.B., Shishodia S., Sandur S.K., et al. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 2006, 72(11):1605-1621.
90. Chavey C., Bibeau F., Gourgou-Bourgade S., et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007, 9(1):R15.
91. Jin L., Yuan R.Q., Fuchs A., et al. Expression of interleukin-1beta in human breast carcinoma. Cancer 1997, 80(3):421-434.
92. Honma S., Shimodaira K., Shimizu Y., et al. The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr J 2002, 49(3):371-377.
93. Lewis A.M., Varghese S., Xu H., et al. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. JTransl Med 2006, 4:48.
94. Bozcuk H., Uslu G., Samur M., et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004, 27(2-3):58-65.
95. Ghosh S., Ashcraft K. An IL-6 link between obesity and cancer. Front Biosci (Elite Ed) 2013, 5:461-478.
96. Barbieri I., Pensa S., Pannellini T., et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 2010, 70(6):2558-2567.
97. Ancrile B., Lim K.H., Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007, 21(14):1714-1719.
98. Schetter A.J., Heegaard N.H., Harris C.C. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31(1):37-49.
99. Subbaramaiah K., Howe L.R., Bhardwaj P., et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011, 4(3):329-346.
100. Morris P.G., Hudis C.A., Giri D., et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011, 4(7):1021-1029.
101. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
102. Vansaun M.N. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res 2013, 19(8):1926-1932.
103. Giordano C., Vizza D., Panza S., et al. Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol 2012, 7(3):379-391.
104. Chen C., Chang Y.C., Lan M.S., et al. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. Int J Oncol 2013, 42(3):1113-1119.
105. Cleary M.P., Juneja S.C., Phillips F.C., et al. Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) 2004, 229(2):182-193.
106. Duan X.F., Tang P., Li Q., et al. Obesity, adipokines, and hepatocellular carcinoma. Int J Cancer 2013, 133(8):1776-1783.
107. Vona-Davis L., Howard-McNatt M., Rose D.P. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007, 8(5):395-408.
108. Duncan B.B., Schmidt M.I., Pankow J.S., et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004, 53(9):2473-2478.
109. Miyoshi Y., Funahashi T., Kihara S., et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003, 9(15):5699-5704.
110. Kim K.Y., Baek A., Hwang J.E., et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 2009, 69(9):4018-4026.
111. Wang Y., Lam J.B., Lam K.S., et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006, 66(23):11462-11470.